EC Number | Application | Comment | Organism |
---|---|---|---|
4.1.1.50 | pharmacology | potentially important drug target for the chemotherapy of proliferative and parasitic diseases | Caenorhabditis elegans |
EC Number | Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
---|---|---|---|---|
4.1.1.50 | 10000 | - |
2 * 32000, alpha, + 2 * 10000, beta, SDS-PAGE | Caenorhabditis elegans |
4.1.1.50 | 32000 | - |
2 * 32000, alpha, + 2 * 10000, beta, SDS-PAGE | Caenorhabditis elegans |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
4.1.1.50 | Caenorhabditis elegans | O02655 | - |
- |
EC Number | Posttranslational Modification | Comment | Organism |
---|---|---|---|
4.1.1.50 | proteolytic modification | alpha-subunit, 32000 Da, and beta-subunit, 10000 Da, are derived from cleavage of the proenzyme. The mRNA has an unusually long 5'-untranslated region of 477 nucleotides. This region has a small open reading frame, which can encode a putative peptide of 17000 residues | Caenorhabditis elegans |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
4.1.1.50 | S-adenosyl-L-methionine | - |
Caenorhabditis elegans | (5-deoxy-5-adenosyl)(3-aminopropyl)methylsulfonium salt + CO2 | - |
? |
EC Number | Subunits | Comment | Organism |
---|---|---|---|
4.1.1.50 | tetramer | 2 * 32000, alpha, + 2 * 10000, beta, SDS-PAGE | Caenorhabditis elegans |